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SUMMARY
The plasma clearance of intravenously injected '25I-labelled insulin-like growth factor I (IGF-
I, n = 13) and IGF-II (n = 12) and their transfer into lymph draining the foreleg of 3 5- to 8-
week-old British Saanen goats was studied. Both peptides were initially distributed into a
volume equivalent to the plasma volume, while the final distribution spaces for IGF-I and
IGF-II were 90 + 9-8 and 125 + 12 ml/kg live weight respectively. There were two phases to the
plasma clearance of both IGF-I and IGF-II, with the half-lives of both phases for IGF-I
(9-6 + 0-9 and 287 + 23 min, first and second phase respectively) being significantly (P < 0 001)
longer than those of IGF-II (4-2 + 0-6 and 172 + 18 min, respectively). The radioactivity
transferred into lymph originated from intact IGF-I and IGF-II as well as degraded products
of these compounds, as assessed by precipitation with trichloroacetic acid and gel filtration.
Levels of undegraded IGF-I in lymph were 50% greater than IGF-II. While more than 90%
of either peptide was bound to specific IGF-binding proteins in plasma, in lymph 34 + 2% of
IGF-I and 23 + 3 % of IGF-II remained in the free form 60-80 min after injection. The
plasma: lymph ratio for free IGF-I was 2: 1 and for bound IGF-I, 8:1. The corresponding
values for IGF-II were 3:2 and 8:1 respectively. These results provide direct experimental
evidence for transfer of undegraded IGF-I and IGF-II from blood into lymph of the foreleg,
consistent with the ability of these factors to act in an endocrine role in growing tissues.
Differences between plasma clearance and transfer of IGF-II into lymph compared with
IGF-I may be due to its greater cellular uptake and/or degradation in vivo.
INTRODUCTION
The somatomedin hypothesis proposed by Salmon & Daughaday (1957) stated that the
growth-promoting activity of growth hormone is mediated by serum sulphation factors.
These were later termed somatomedins (Daughaday, Hall, Raben, Salmon, Van Den
Brande & Van Wyk, 1972) and then insulin-like growth factors I and II (IGF-I and
IGF-II; Daughaday, Hall, Salmon, Van Den Brande & Van Wyk, 1987). The search for the
source of IGFs revealed the majority of tissues have the capacity to produce IGF-I and
IGF-II (D'Ercole, Stiles & Underwood, 1984; Matthews, Norstedt & Palmiter, 1986;
Murphy, Bell & Friesen, 1987), but blood appears to be the major store of these factors
(D'Ercole et al. 1984).
IGFs in plasma are bound to specific high-affinity binding proteins which may be
separated by gel filtration at positions corresponding to approximate molecular weights of
150 and 40 kDa (see Ooi & Herington, 1988; Baxter & Martin, 1989 a; Holly & Wass, 1989;
Clemmons, 1991). The 150 kDa protein binds most of the circulating IGFs and consists
of three subunits; IGF, an acid-stable IGF binding unit and an acid-labile unit which helps
* Present address to which reprint requests should be sent: Ruakura Agricultural Centre, Private Bag,
Hamilton, New Zealand.
C. G. PROSSER, M. D. BAUCELLS AND I. R. FLEET
form the 150 kDa complex but does not in itself bind IGF (Baxter & Martin, 1989 b).
Plasma also contains several binding proteins of approximately 40 kDa which together
bind only a small proportion of total circulating IGF. Extravascular fluids, such as lymph
or cerebral spinal fluid also contain several binding proteins of around 40 kDa and small
amounts of the 150 kDa complex (Ooi & Herington, 1988; Baxter & Martin, 1989 a;
Hodgkinson, Moore, Napier, Davis, Bass & Gluckman, 1989 b; Lord, Martin, Walton,
Ballard & Read, 1991). Accurate measurement of the quantity of unbound IGF in
circulation is difficult because of the very small amounts present, but it is thought that this
might comprise less than I % of total circulating IGF (Daughaday, Ward, Goldberg,
Trivedi & Kapadia, 1982).
For circulating IGFs to act in vivo they must be able to traverse the capillary endothelial
barrier between them and the target tissues. Experiments in vitro suggest exogenously
added IGF-I and IGF-II are internalized by bovine capillary endothelial cells and
subsequently released into the medium in an undegraded form (Banskota, Carpentier &
King, 1986; Bar, Boes & Yorek, 1986), but whether such a vectorial pathway exists in vivo
is not known. In the present study we studied the transfer of IGF-I and IGF-II from blood
into lymph draining the foreleg of 3- to 8-week-old goats to examine the ability of these
peptides to pass undegraded into the extracelluar fluid space of a group of tissues
undergoing rapid growth, presumably partly under control of IGFs. Some of these results
have been presented elsewhere in a preliminary form (Baucells, Fleet & Prosser, 1989).
METHODS
Materials
Recombinant human IGF-I and IGF-II were obtained from Bachem UK (Saffron Walden,
Cambs). TSK Fractogel HW-55(S) and Triton X-100 were purchased from BDH Chemicals Ltd
(Poole, Dorset). Sephacryl S-200, Sephadex G-75(F) and Sephadex G-50(F) were supplied by
Pharmacia (Uppsala, Sweden). lodogen was from Pierce Europe B.V. (Oud-Beijerland, Netherlands)
and bovine serum albumin (BSA) and tris(hydroxymethyl)aminomethane (Tris) were from Sigma
(St Louis, MO, USA). All other chemicals were of reagent grade.
Iodination of IGF-I and IGF-II
IGF-I and IGF-II were iodinated utilizing iodogen similar to the method outlined by Salacinski,
McLean, Sykes, Clement-Jones & Lowry (1981). lodogen was dissolved in dichloromethane to give
a final concentration of 1 mg/ml. Aliquots containing 2 ,ug were added to polypropylene Eppendorf
tubes and dried under a stream of nitrogen. IGF-I (2 ,ag in 40 j1 of 10 mM-HCl), 6 ,ul of a solution of
0-1 M-Tris with 0 5% (vol/vol) Triton X-100 and 5 ,ul of Na['251] (0 5 mCi, Amersham International
plc, Bucks) was added to the tube of iodogen. The iodination was allowed to continue for 10 min at
room temperature, then stopped by adding 0-5 ml of 0-05 M-sodium phosphate buffer pH 74,
containing 0 15 M-sodium chloride and 0 2 g/l sodium azide (PBS). The tubes were mixed and left at
room temperature for a further 5 min before transferring the contents to a I x 30 cm column of
Sephadex G-50. The '25I-labelled IGFs were eluted with PBS containing 0-1 mg/ml BSA at a flow of
approximately 10 ml/h. Typically, 78-91 % incorporation of 1251 was achieved giving specific
activities between 190 and 225 juCi/jug protein. The iodinated material was stored frozen and used
within 10 days of iodination. At least 95% of the label was precipitable with 10% (vol/vol)
trichloroacetic acid (TCA) on the day of use.
Lymph collection and plasma clearance of 125I-IGF
The experiments were performed on twenty-five 3 5- to 8-week-old British Saanen male goats of
7 5-14 kg live weight. The animals had been weaned at least 10 days preceding the experiment and
maintained on a diet of concentrates with hay and water ab libitum. The animals were allowed free
access to their food up to 30 min before anaesthesia. Anaesthesia was induced and maintained with
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sodium pentobarbitone (25 mg/kg) injected intravenously via a catheter (1 2 mm o.d., 0 8 mm i.d.;
polypropylene tubing; Dural Plastics, NSW, Australia) inserted into the jugular vein. After
intubation, oxygen inhalation was maintained in a closed circuit rebreathing apparatus with CO2
removed by soda lime. A subclavian efferent lymph duct draining the foreleg was cannulated with
polyvinyl tubing (0 8 mm o.d. 0-5 mm i.d.). The lymph drained into tared polystyrene tubes
containing 10 ,l of 0.5 M-disodium ethylenediaminetetra-acetic acid (EDTA) as an anticoagulant.
The collecting tube was changed every 10 min and stored on ice until analysis. Lymph flow rate
(ml/min) was determined gravimetrically assuming a lymph density of 101 g/ml.
125I-IGF-I (4-18-5 ,uCi in 0-5 ml) was injected into the jugular vein of thirteen kid goats and 125I-IGF-
11 (6-16 ,uCi in 0-5 ml) into twelve kids. Any material remaining in the catheter was flushed into the
animal with sterile saline. Samples (1 ml) of arterial blood were withdrawn at 0 5, 1, 2, 3, 4, 5, 10 min
and thereafter at 10 min intervals, coinciding with the changing of the lymph collection tubes, via a
catheter (1.2 mm o.d., 0 8 mm i.d., polyethylene tubing) inserted into the carotid artery. The samples
were put into polystyrene tubes containing EDTA, and plasma prepared by centrifugation (1500 g,
15 min). The sampling was continued for 4 h.
Total radioactivity present in 0 5 ml aliquots of plasma and weighed lymph samples was measured
in a y-counting system (Cobra 5005, Packard). Precipitation of undegraded peptide was achieved
with 10% (final vol/vol) TCA.
Estimation ofplasma volume
Plasma volume was estimated by dilution of 1 5-2 g of 1% (wt/vol) solution of Evans Blue dye
injected intravenously (Little & Williams, 1964). Samples of arterial blood (2 ml) were taken at 3, 5
and 7 min following injection.
Gel filtration ofplasma and lymph
Samples of plasma and lymph, taken after the radioactivity had reached maximum in lymph (60-80
min), were applied to a 1 8 x 35 cm column of TSK Fractogel HW-55(S) previously equilibrated with
PBS (pH 74) containing 0 1 mg/ml BSA. Fractions of 0 5 ml were collected at a flow of 1 ml/min. The
column was calibrated with Blue Dextran, ovalbumin, 125I-IGF-I and potassium dichromate. Some
samples of plasma and lymph were also chromatographed on a 0.5 x 30 cm column of Sephacryl S-
200, equilibrated with PBS containing 01 mg/ml BSA. Fractions of I ml were collected at a flow of
0.5 ml/min. To determine whether the radioactivity eluting > 7000 Da was authentic IGF that was
associated with binding proteins, plasma was diluted with 1 vol of 2 M-acetic acid (pH 2 8), mixed and
left for 0-5 h at 4 'C. The sample was transferred onto a Sephadex G-75 column (0 5 x 30 cm) and
eluted with 1 M-acetic acid (pH 25) at 05 ml /min. The elution position of authentic IGF was
determined by chromatography of 125I-IGF-I under the same conditions.
Ligand blotting
A modification of the Western blotting technique was employed to detect IGF binding activity in
plasma and lymph. Samples of plasma (4 ,ul) and lymph (8 ,l), supplemented with glycerol, Tris (pH
8 6), sodium dodecyl sulphate (SDS) and Bromophenol Blue, were electrophoresed under non-
reducing conditions on 12% (wt/vol) polyacrylamide gel containing 01% SDS (wt/vol). The
separated proteins were transferred electrophoretically to nitrocellulose membrane, which was
treated exactly as described by Hossenlopp, Seurin, Segovia-Quinson, Hardouin & Binoux (1986)
using '251-IGF-I or 1251-IGF-II as the ligand.
Analysis of data
The clearance of TCA-precipitable radioactivity from plasma was fitted by non-linear regression
analysis employing differential equations (Bevington, 1969). The half-lives and volumes of
distribution of the two components of the decay curve were calculated according to the methods
described by Tait, Tait, Little & Laumas (1960). In order to remove any variation arising from the
use of animals with different body weights and therefore different volumes of body water, the
radioactivity in lymph was expressed as a percentage of the calculated amount in plasma at time zero.
This latter value was obtained by extrapolation of the decay curves to zero on the time axis using the
equations generated from the individual animal's decay curve. Although the shapes of the subsequent
577
C. G. PROSSER, M. D. BAUCELLS AND I. R. FLEET
curves were not different from those generated from the raw data, this transformation allows more
accurate assessment of the relative amounts of '251-labelled IGF-I or IGF-II transferred into lymph.
RESULTS
Plasma
Both 125I-labelled IGF-I and IGF-IL appeared in arterial plasma as TCA-precipitable
and TCA-soluble radioactivity following their injection into the jugular vein. The time
course of clearance of TCA-precipitable radioactivity from arterial plasma is shown in
Fig. 1. The radioactivity present in plasma eluted from Fractogel HW-55(S) column, run at
neutral pH, at positions corresponding to high molecular weight binding proteins, free IGF
and the salt peak (Fig. 2). This indicates the presence of undegraded and degraded
fragments of IGF. When plasma was subjected to gel filtration on Sephadex G-75 at acid
pH, thereby disrupting the IGF-binding protein interaction, the major peak of radioactivity
eluted as free 1251-IGF. When corrected for procedural losses the amount eluting at this
position was indistinguishable from the quantity of TCA-precipitable material in that
sample, indicating this material was authentic IGF.
The proportion of total radioactivity in plasma which was TCA precipitable decreased
progressively with time (Fig. 3). While there was no difference in this value for IGF-I and
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Fig. 1. Time course of clearance of trichloroacetic acid (TCA)-precipitable radioactivity from arterial plasma
and appearance in lymph following intravenous injection of "251-labelled IGF-I (0, D) and IGF-II (-, *) in
3 5- to 8-week-old goats. Levels of TCA-precipitable radioactivity in lymph of kid goats were expressed as a
percentage of the amount in plasma at time zero (to) to reduce inter-animal variation. All values are
means+S.E.M. of thirteen experiments for IGF-I and twelve experiments for IGF-II. Note the use of a
logarithmic scale for plasma radioactivity. Error bars for plasma data are smaller than the symbols and not
shown.
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Fig. 4. Autoraidiogriaph showxi-ng binding of 125 I-IGF-I and I _AIG-H to pirote'ins fr-omi Iymph L. 8 /1) 01-
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IGF-II over the fir-st 10 mmn. betweeni 10 and 60 min the vaites for- IGF-II declinied mior-e
rapdly thani IGF-1. By 60 mnm the differenices between IGF-1 anid IGF-11 wer-e statistically
sgificant (P < 0-05, test) and this was maintainedfrtermidro theiexerimet.
The clearanice of TCA-precipitable radioactivity, whichi represenits aulthentic IGF, fromi
plasmia was best descri-bed by ani exponiential decay CUrve withi two phlases. The half-lives
of these phases and the iniitial and finial distribuItion k'~OIlute of 1251-l'abelled IGF-l and IGF-
II are given in Table I. The initial (0-10 mmii) volumie of distributioni for IGF-I and IGF-
II were the samIne and agr-eed with the plasnmt volume of the goats cas meiasured by diluitionl
of Evans BILue. The half-lives of both componients of the dec-ay curve for IGF-11 were
sinficanitly shorter thani those of IGF-1. In conitrast, the finial distribUtion Volumire for IGF-
II was 37%1) greater than that of IGF-1.
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Table 1. Half-lives and distribution volumes of '251-labelled IGF-I and IGF-II in 3-5- to
8-week-old goats
IGF-I IGF-II
Half-life of component 1 (min) 9 6+009 4 2 + 0 6**
Half-life of component 2 (min) 287 + 23 172 + 16**
Initial distribution volume (ml/kg live weight) 45+3 52+5
Final distribution volume (ml/kg live weight) 90+ 10 125 + 12*
Plasma volume (ml/kg live weight) 42 + 2 50 + 3
The half-lives of the two phases for plasma clearance of peptides were calculated from the double exponential
decay curves fitted to the data by regression analysis. Values are means+ S.E.M. of thirteen experiments for IGF-
I and twelve for IGF-II. Plasma volume, measured by dilution of Evans Blue, was measured in four animals from
the IGF-I group, but all twelve animals from the IGF-II group. Differences between IGF-I and IGF-IT were tested
using unpaired t test; *P < 005, **P < 0001.
To determine the association of undegraded '25I-labelled IGF with plasma binding
proteins, plasma taken between 60 and 80 min was subjected to gel filtration on Fractogel
HW-55(S) at neutral pH. In confirmation of the report by Hodgkinson, Davis, Moore,
Henderson & Gluckman (1989a) there was no evidence of dissociation of IGF-I or IGF-
II from plasma binding proteins during storage. The percentage bound '25I-IGF-I in
plasma from freshly drawn blood was 92 % and after 6 h at 20 °C or 8 h at 4 °C the
percentages were 93 and 91 % respectively. The corresponding values for 125I-IGF-II were
94, 94 and 92 % respectively. It was estimated that 91 1 + 0 9 % of 1"5I-IGF-I was associated
with binding proteins, while 7+ 2 % remained in the free form. The proportions of bound
and free '25I-IGF-II were 92+ 2 and 6+ 2 % respectively.
Lymph
Like plasma, radioactivity in lymph consisted of TCA-precipitable and TCA-soluble
material which eluted from Fractogel HW-55(S) at positions corresponding to bound and
free IGF and at, or near, the salt peak for the column (Fig. 2). The amount of radioactivity
eluting as bound and free IGF in lymph was identical to that which was TCA precipitable.
The proportion of total radioactivity in lymph which was undegraded was much less than
in plasma (Fig. 3). Like plasma, more of the radioactivity derived from IGF-II was present
as degraded products than for IGF-I (Fig. 3).
The time course of appearance of TCA-precipitable radioactivity in lymph is given in
Fig. 1. '25I-IGF-I reached its peak in lymph by 20 min, but maximum values for 125I-IGF-
II were not attained until at least 60 min. After these times the amount of 125I-IGF-I and
'25I-IGF-II declined very slowly at a similar rate for both peptides. At the times when
maximum values for each peptide were obtained in lymph, the amount of 1251-IGF-I was
50% greater than 125I-IGF-II.
In lymph taken between 60 and 80 min after the injection of IGFs, 66+ 3 % of 125I-IGF-
I was associated with binding proteins, while 34 + 2% was present in the free form. The
corresponding values for 125I-IGF-II were 77+ 3 and 23+ 3 % respectively. The differences
between IGF-I and IGF-II were significant at P < 0-02. The ratio of free 125I-IGF-I in
plasma to that in lymph was 14 + 03: 1, whereas the same ratio for bound 125I-IGF-I was
8-5 + 0 8: 1. For 125I-IGF-II these ratios were 1 5+0 3: 1 and 8 1 + 1-3: 1 respectively.
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Ligand blotting
Ligand blotting of plasma and lymph revealed six binding species with approximate
molecular weights of 46, 41, 36, 32, 31 and 27 kDa (Fig. 4). All IGF-binding proteins
species present in plasma were found in lymph and detected with either IGF-I or IGF-II.
However, the intensity of labelling was less in lymph, even though twice as much lymph
(8,ll) was added compared with plasma (4,ul), indicating the latter contained substantially
more IGF-binding activity. The pattern of labelling was also very similar for IGF-I or IGF-
II, although the protein of molecular weight of 36 kDa exhibited a greater intensity of
labelling using125I-IGF-II compared with125I-IGF-I.
DISCUSSION
The pattern of clearance of125I-IGF-I from plasma and its calculated half-life following its
intravenous injection into 3- to 8-week-old goats is similar to that obtained in lambs
(Francis, McNamara, Filsell & Ballard, 1988) and mature sheep (Hodgkinson, Davis,
Burleigh, Henderson & Gluckman, 1987). The clearance of injected125I-IGF-II from kid
goats and sheep (Hodgkinson et al. 1989a) follows essentially the same form, but with a
significantly shorter half-life than IGF-I. In confirmation of the report of Francis et al.
(1988) we found that clearance of "25I-labelled IGF-I and IGF-II from plasma was
associated with steadily increasing amounts of TCA-soluble material in the circulation.
Column chromatography of plasma revealed this material probably represented degraded
products of IGFs. These were presumably formed in vivo after internalization of the peptide
by cells (Banskota, et al., 1986; Bar, et al., 1986; Schalch, Sessions, Farley, Masakawa,
Elmer & Dills, 1986) and subsequent release of breakdown products back into the
circulation or from degradation by ectoproteases present on the surface of endothelial cells.
The greater proportion of TCA-soluble material in lymph compared to that in plasma is
in keeping with the former hypothesis since the cellular breakdown products would be
released firstly into the interstitial fluid which contributes to lymph composition.
The '25I-IGF-I or IGF-II was rapidly (within 10 min) distributed into a volume identical
to the plasma volume of the kid goats. The final volume of distribution, however, was far
less than the extracelluar fluid space (approximately 20 % of body mass), implying that
these compounds have only restricted ability to cross the capillary endothelium. However,
the presence of undegraded IGFs in lymph of the foreleg suggests transfer across the
vascular endothelium of tissues in this region does occur in vivo.
Gel filtration revealed that between 60-80 min after their injection the IGFs were present
in lymph as free and protein-bound peptide. Although the column resolution was not
sufficient to allow direct comparison of the different binding proteins present in plasma or
lymph, ligand blotting demonstrated the presence of identical proteins in lymph and
plasma, albeit at much lower amounts in lymph. This binding profile for lymph from goats
was also observed by Lord et al. (1991) for lambs and Davis, Hodgkinson, Prosser &
Gluckman (1992) for sheep, but differs from human lymph (Binoux & Hossenlopp, 1988)
in that the latter is virtually devoid of the doublet running at 41-46 kDa.
A significantly greater proportion of IGFs in lymph were present in the free form
(34 + 2 % for IGF-I and 23+ 2% for IGF-II) compared with plasma (7+ 2 and 6 + 2 % for
IGF-I and IGF-II respectively). Levels of free IGF-I and IGF-II present in plasma were less
than twofold greater than those in lymph, similar to the plasma: lymph ratio for insulin in
dogs (Yang, Hope, Alder & Bergman, 1989), but there was 8 times as much protein-bound
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IGF-I and IGF-II in plasma as in lymph. The ability of binding proteins to maintain
circulating levels of IGF-I has previously been demonstrated using analogues (Cascieri,
Saperstein, Hayes, Green, Chicchi, Appelbaum & Bayne, 1988; Ballard, Knowles, Walton,
Edson, Owens, Mohler & Ferraiolo, 1991), and reduced forms of this peptide (Francis
et al. 1988) which have a much lower affinity for plasma binding proteins and are
consequently cleared more rapidly. The present findings demonstrate that in the intact
animal both IGF-I and IGF-II cleared from plasma is transferred into the extracellular fluid
space of at least the foreleg in an undegraded form.
The basis for the retention of protein-bound IGF within the vascular space may relate
simply to the greater exclusion of large molecular weight proteins from the normal routes
of transendothelial transfer (Palade, Simionescu & Simionescu, 1979). Alternatively, if
IGFs are transported by a receptor-mediated process similar to insulin (King & Johnson,
1985), the binding proteins might act to restrict binding of IGFs to insulin receptors. This
would ensure that transfer is regulated by the relative presence within the capillary bed of
specific receptors for IGF (Bar & Boes, 1984; Jialal, Crettaz, Hachiya, Kahn, Moses,
Buzney & King, 1985). More recent evidence suggests that the binding proteins themselves
might be instrumental in regulating transfer of IGFs across the capillary endothelium (Bar,
Boes, Duke, Sandra, Bayne, Cascieri & Booth, 1990).
The present study highlights several major differences between the in vivo processing of
plasma IGF-I and IGF-II. Firstly, IGF-II was distributed into a 37 % larger volume at
equilibrium compared with IGF-I. Secondly, it took 3 times longer for 125I-IGF-II to reach
maximum in lymph, although its clearance from plasma was more rapid than 125I-IGF-I.
Thirdly, 50% more 125I-IGF-I transferred into lymph was TCA precipitable compared with
125I-IGF-II, but significantly more of the latter was released into lymph and plasma in a
degraded form.
The explanation of these differences may lie with different rates of uptake and
degradation of the two growth factors. Since the composition of lymph is determined both
by transfer of substances from the vascular space into interstitial fluid and cellular function
(Palade, et al. 1979), if any substance is internalized by cells and only its degraded
fragments released, the content of this substance in lymph will be reduced. As the
proportion of TCA-soluble radioactivity in both lymph and plasma was greater for IGF-
II than IGF-I we would predict that either more IGF-II was internalized by cells or it was
more readily degraded. A greater cellular uptake of IGF-II may be inferred from its larger
volume of distribution in vivo and studies in vitro which demonstrate more internalization
and degradation of 1251-IGF-II by capillary endothelial cells compared with 1251-IGF-I
(Bar et al. 1986). Thus, the more rapid clearance of 1251-IGF-II from plasma as well as its
slower equilibrium and lower concentration in lymph may be explained by its greater
cellular uptake and/or degradation compared with 1251-IGF-I. It is interesting to speculate
that binding proteins present in plasma and lymph might play a central role in this process,
given that these have differing affinities for the IGFs (Hodgkinson et al. 1989 b) and can
influence the availability of IGFs to cell receptors (see Ooi & Herington, 1988; Baxter &
Martin, 1989a; Clemmons, 1991).
In conclusion, the present results provide direct experimental evidence for vectorial
transfer of undegraded '25I-labelled IGF-I and IGF-II from the circulation into the
extracelluar fluid space of the foreleg of young goats. This is in keeping with the ability of
these factors to act in an endocrine fashion in a group of tissues undergoing rapid growth.
The finding that levels of IGF-I and IGF-II in lymph were maintained, declining only as
those in plasma decreased, reinforces the proposed role of plasma binding proteins as
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'storage' complexes, helping to maintain constant exposure of target tissues to IGF.
Clearly, the mechanism of transfer of IGF across the vascular endothelium as well as its
regulation requires further investigation.
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